Author:
Zhou Zhi-rui,Yang Zhao-zhi,Wang Shao-jia,Zhang Li,Luo Ju-rui,Feng Yan,Yu Xiao-li,Chen Xing-xing,Guo Xiao-mao
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference34 articles.
1. Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, et al. The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 2014; 6: 1329–35.
2. Hou J, Zhou Z, Chen X, Zhao R, Yang Z, Wei N, et al. HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo. Oncotarget 2016; 7: 45186–98.
3. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J . Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 1419–26.
4. Efimova EV, Mauceri HJ, Golden DW, Labay E, Bindokas VP, Darga TE, et al. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res 2010; 70: 6277–82.
5. Chen X, Yu X, Chen J, Yang Z, Shao Z, Zhang Z, et al. Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1–T2 disease and one to three positive lymph nodes after mastectomy. Oncologist 2013; 18: 141–7.
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献